Alpha-D- galactoside galactohydrolase
Alpha-D- galactoside galactohydrolase Brand names, Alpha-D- galactoside galactohydrolase Analogs
Alpha-D- galactoside galactohydrolase Brand Names Mixture
- No information avaliable
Alpha-D- galactoside galactohydrolase Chemical_Formula
C2029H3080N544O587S27
Alpha-D- galactoside galactohydrolase RX_link
http://www.rxlist.com/cgi/generic3/fabrazyme.htm
Alpha-D- galactoside galactohydrolase fda sheet
Alpha-D- galactoside galactohydrolase msds (material safety sheet)
Alpha-D- galactoside galactohydrolase Synthesis Reference
No information avaliable
Alpha-D- galactoside galactohydrolase Molecular Weight
45351.6
Alpha-D- galactoside galactohydrolase Melting Point
No information avaliable
Alpha-D- galactoside galactohydrolase H2O Solubility
No information avaliable
Alpha-D- galactoside galactohydrolase State
Liquid
Alpha-D- galactoside galactohydrolase LogP
-0.307
Alpha-D- galactoside galactohydrolase Dosage Forms
Powder for solution
Alpha-D- galactoside galactohydrolase Indication
For treatment of Fabry's disease (alpha-galactosidase A deficiency)
Alpha-D- galactoside galactohydrolase Pharmacology
Used in the treatment of Fabry disease, an X-linked genetic disorder of glycosphingolipid metabolism. The disease is characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A, which leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues. Clinical manifestations of Fabry disease include renal failure, cardiomyopathy, and cerebrovascular accidents. Fabrazyme is intended to provide an exogenous source of alpha-galactosidase A and to limit the accumulation of these glycolipids in the tissues.
Alpha-D- galactoside galactohydrolase Absorption
No information avaliable
Alpha-D- galactoside galactohydrolase side effects and Toxicity
No information avaliable
Alpha-D- galactoside galactohydrolase Patient Information
BIOD00075.html
Alpha-D- galactoside galactohydrolase Organisms Affected
Humans and other mammals
